PROLOR Biotech — Technical Presentation (May 2012)
23 slides from PROLOR Biotech's technical presentation, May 7, 2012
Slide 1: Protein.Longevity. Redefined
Protein.Longevity. Redefined May 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments of PROLOR’s long-acting protein programs and are made pursuant to the safe harbour provisions of the Private Securities Litigation R
Slide 3: Once-Weekly CTP-Modified hGH (MOD-4023) Phase II Study
Once-Weekly, CTP-Modified hGH (MOD-4023) Maintains IGF-1 Levels in Growth Hormone Deficient Adults: A Phase II, Dose and Frequency Finding Study 3
Slide 4: Prolor's Technology (CTP) Increases Protein Circulation Time
Prolor’s Technology (CTP) Increases Protein Circulation Time CTP A Natural Peptide Created During Evolution to Enhance Longevity of the Hormone hCG Two fertility hormones The CTP “cassette” hCG maintains pregnancy and requires long T1/2 hLH stimulates ovulation on a pulse mode requiring a short T1/2
Slide 5: A Phase II, Dose-Finding Study of MOD-4023 in Growth Hormone Deficient Adults
A Phase II, Dose-Finding Study of MO D -4023 in Phase II design Growth Hormone Deficient Adults (GHDA) A Phase II, Randomized, Open-Label, Comparative Dose Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MOD-4023 in Growth Hormone Deficient Adults (GHDA) Stud
Slide 6: Phase II Study Objectives
A Phase II, Dose-Finding Study of MO D -4023 in Phase II design Growth Hormone Deficient Adults (GHDA) Primary objective: To assess the safety and tolerability of different doses of MOD-4023 in pre-treated Adult GHD patients after administration of four once-weekly S.C. doses; Secondary objectives:
Slide 7: MOD-4023 Phase II Study Design
MOD-4023 Phase II StudyPhase II design Design Stage I (4 weeks treatment) Stage II (4 months treatment) Optimization MOD 4023 Data Analysis (Daily hGH (4 wks) (Daily hGH 8-50 wks) MOD-4023 Treatment (4 months) 2-8 wks) Dose 30% EW . MOD-4023 dose titration period : Dose 45% EW All patients start on
Slide 8: Study Status-Demographics
Study Status-Demographics 30% of Weekly 45% of Weekly 100% of Weekly Characteristic Cumulative hGH Cumulative hGH Cumulative hGH dose dose (N=13) dose (N=13) (N=13) Age (years) Mean (SD) 40.9 (13.0) 41.5 (10.8) 40.5 (11.1) Min-Max 25 - 60 25 - 58 23 - 59 Gender, n (%) Male 11 (85) 11 (85) 11 (85) Fe
Slide 9: Phase II Stage I (4 weeks) Positive Data: IGF-1 in 33 Males
MOD-4023 Phase II-Stage I (4 weeks) Positive Data -- IGF-1 in 33 Males -- Prior to first injection Full week profile after last injection 2 0 Serum IGF-1 SDS -2 -4 -6 28/33 male patients have an Average IGF-I SDS within the normal range (±2 SDS) after only one month of treatment. -8 -48 -24 0 24 48
Slide 10: Phase II-4 Months Extension Period
Phase II-4 Months Extension Period 10
Slide 11: Stage II (4 Months Extension Period) Study Design
Stage II (4 Months Extension Period) Study Design Patients who participated in first part of the study (including the EOW cohorts) 16-weeks once-weekly treatment Starting dose-50% of cumulative weekly dose IGF-1 measured every two weeks on day 3 or 4 post dose Dose modified once monthly if IGF-1 SDS
Slide 12: Stage II (4 Months Extension Period)
Stage II (4 Months Extension Period) V’ 2 V’ 3 V’ 4 V’ 5 V’ 6 V’ 7 V’ 8 V’ 9 V’ 10 1 st 2nd 3 rd 4 th 5th 6th 7th 8th 9th 10 th 11 th 12 th 13 th 14 th 15 th 16 th V’ 3a V’ 5a V’ 7a 12
Slide 13: MOD-4023 Maintains IGF-1 Levels Within Normal Range During 16 Weeks
MOD-4023 Effectively Maintains IGF-1 Levels Within Normal Range During the 16 Weeks Extension Study IGF-1 measured every second week on day 4 after injection Daily Treatment Single Weekly Injection MOD-4023 Treatment 3.00 2.00 Stabilization 1.00 around normal 0.00 range after 4 -1.00 months of treat
Slide 14: MOD-4023 Maintains IGF-1 Within Narrow Normal Range (±1.5 SDS)
MOD-4023 is Effective in Maintaining IGF-1 Levels Within Narrow Normal Range (± 1.5SDS) Within Restricted Within Normal Normal Range ± 1.5 Range ± 2 SDS SDS Daily GH Treated, Entering 4 Months 36/42 (86%) 29/42 (69%) Study MOD-4023 Treated, 37/42 (88%) 34/42 (81%) Post 4 Months Study 14
Slide 15: MOD-4023 Extension Period Interim Analysis & Conclusions
MOD-4023 Extension Period -- Interim Analysis & Conclusions-- Single weekly injection of MOD-4023 can replace 7 consecutive daily GH injections. Exploratory study demonstrated potential for twice monthly injection regimen. Only 50-65% of the cumulative weekly dose was required to maintain the majori
Slide 16: MOD-4023 Phase III
MOD-4023 Phase III Efficacy Objective: to demonstrate a clinical superiority of MOD-4023 over placebo in adult GHD patients (naïve or not currently treated) Safety Objective: Evaluate safety and tolerability of MOD-4023 Patients: Recruit 150 adult GHD patients Design: Screening period of up to 28 da
Slide 17: Many Thanks to PIs who Participated in the Phase II Study
Many Thanks to PIs who Participated in the Phase II Study Investigators Medical site Ass. Prof. Dr. Laszlo Bajnok, MD, PhD Pecs, Hungary Prof. Jan Cap, MD, PhD Hradec Kralove, Czech Republic Prof. Benjamin Glaser, MD Jerusalem, Israel Prof. Miklos Goth MD, PhD Budapest, Hungary Yona Greenman, MD Tel
Slide 18: Thank You For Your Attention
Thank You For Your Attention 18
Slide 19: Deficiencies of Other Axes
Deficiencies of Other Axes 30% of Weekly 45% of Weekly 100% of Weekly Pituitary Axes Cumulative hGH dose Cumulative hGH dose Cumulative hGH (N=13) (N=13) dose (N=13) N (%) N (%) N (%) Thyroid Axis Deficiency 12 (92%) 12 (92%) 13 (100%) Gonadal Axis Deficiency 11 (85%) 13 (100%) 11 (85%) Adrenal Axis
Slide 20: Summary of Pharmacokinetic Parameters for MOD-4023
Summary of Pharmacokinetic Parameters for MOD-4023 (Corrected for Net hGH Content) Cohort† Parameter* 30% of weekly dose2 45% of weekly dose3 100% of weekly dose1a Dose (mg) 0.72 ± 0.34 (11) 0.76 ± 0.39 (11) 3.29 ± 1.820 (11) Cmax (ng/mL) 1.55 ± 1.62 (11) 2.38 ± 2.50 (11) 8.41 ± 8.618 (11) Tmax (h)
Slide 21: hGH-CTP Phase II: Dose Kinetics
hGH-CTP Phase II: Dose Kinetics Mean Serum MOD-4023 levels following last MOD-4023 dose -50 0 50 100 150 200 Hours after dose 21 100000.00 Cohort 2-30% wk-1.33mg Cohort 3-45% wk-1.4mg Cohort 5-100% wk-5.35mg 10000.00 (pg/ml) 1000.00 MOD-4023 Serum levels 100.00 10.00 1.00
Slide 22: Summary of Dose Modifications During Stage II
Summary of Dose Modifications During Stage II Number of Dose Males Females Modifications No dose modifications 22 (out of 34) 3 (of 8) 1 dose modification 6 (out of 34) 1 (out of 8) 2 dose modifications 3 (out of 34) 3 (out of 8) 3 dose modifications 3 (out of 34) 1 (out of 8) 22
Slide 23: Summary of Patients Having IGF-I SDS Within Normal Range After 16 Weeks
Summary of Patients Having IGF-I SDS Within Normal Range Following 16 Weeks of Treatment All Patients Males Females 37 (out of 42)* 31 (out of 34) 6 (of 8) * 4 patients below -2 SDS and 1 patient above +2 SDS. 23